Search Results: All recruiting trials found

Main Trials Page | Search Trials | Clinical Trial Site List | Drug Watch List

First-line Trials |Gleevec/Sutent-resistant | All Trials | Recruiting Trials | Preventative (Adjuvant)Treatment Trials

 
81 trials found
Page 1 of 2 | Next | Last

 

Note: The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database. Click on the name (title) to see the trial details in the LRG database. Click on the NCT link (below) to see the trial details in ClinicalTrials.gov.
Drug
NCT#
Name
Phase
Imatinib
NCT00367861
Prospective Multicentric Randomized Study of GlivecĀ® in Advanced Gastrointestinal Stromal Tumors Expressing c-Kit: Interruption After 5 Years vs Maintenance
3
       
Imatinib
A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.
3
       
Imatinib
NCT01031628
Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients
3
       
Masitinib, (AB1010)
NCT00812240
Efficacy and Safety of Masitinib (AB1010) in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour
3
       
Nilotinib or Imatinib
NCT00751036
Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg (LANGIST)
3
       
Nilotinib or Imatinib
NCT00785785
Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients
3
       
Sunitinib
NCT00094029
A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248
3
       
BIIB021 (CNF2024)
NCT00618319
An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) Refractory to, Intolerant of, or Not a Candidate for Imatinib and Sunitinib Treatment
2
       
Dasatinib (BMS-354825)
NCT00568750
Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors
2
       
Imatinib
NCT00112632
Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
2
       
Imatinib
NCT00290485
Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)
2
       
Imatinib
NCT00764595
Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor
2
       
Imatinib
NCT00867113
Five Year Adjuvant Imatinib Mesylate (GleevecĀ®) in Gastrointestinal Stromal Tumor (GIST)
2
       
Imatinib, Nilotinib
REGISTER: A multicentre phase 2 study of risk evaluation in GIST with selective therapy escalation for response
2
       
Nilotinib
NCT00782834
Nilotinib in Advanced GIST
2
       
Nilotinib
NCT00756509
Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib. (OPEN)
2
       
Nilotinib
NCT00633295
Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor
2
       
Regorafenib
NCT01068769
Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
2
       
Sorafenib (Nexavar, BAY 43-9006)
NCT00265798
Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate
2
       
STA-9090
NCT01039519
A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)
2
       
Sunitinib
NCT01054911
Evaluation of Patients With Bulky GIST Using Sunitinib
2
       
Surgery
NCT00769782
Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor
2
       
Radiation
NCT00515931
Radiation Therapy as Palliative Treatment of GIST (GIST-RT)
1
       
Nilotinib
NCT00976612
Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST)
       
None
NCT00507273
Gastrointestinal Stromal Tumors (GIST) Registry
       
NCT00777504
Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors
4
       
Sunitinib
NCT00428220
A Continuation Study To Provide Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
3
       
Dasatinib (BMS-354825)
NCT00464620
Trial of Dasatinib in Advanced Sarcomas
2
       
Everolimus
NCT00767819
Treatment of Patients With RAD001 Who Have Progressive Sarcoma
2
       
Gemcitabine, docetaxel
NCT00359333
Phase II Trial of Locally Advanced/Metastatic Soft Tissue Sarcoma or Imatinib Mesylate Refractory Advanced/Metastatic Malignant GIST
2
       
Dasatinib (BMS-354825) + Bevacizumab
NCT00792545
Dasatinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery
1
       
Doxorubicin + Flavopiridol
NCT00098579
Doxorubicin and Flavopiridol in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery
1
       
Imatinib + IL-2
Imatinib + IL-2
1
       
Multi-bacteria vaccine (MBV)
NCT00623831
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen.
1
       
PLX3397
NCT01004861
Safety Study of PLX108-01 in Patients With Solid Tumors
1
       
SF1126
NCT00907205
A Phase I Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study in SF1126, a PI Kinase (PI3K) Inhibitor, Given Twice Weekly by IV Infusion to Patients With Advanced or Metastatic Tumors
1
       
Sunitinib or Sorafenib
NCT00979329
Study on the Influence of Sunitinib and Sorafenib on Fatigue, Quality of Life and Depression in Patients With Metastatic Renal Cell Cancer or Gastrointestinal Stromal Tumor (GIST)
       
AUY922
NCT00526045
Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients.
1
       
BGT226
NCT00600275
A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
1
       
GDC-0941 + GDC-0973
NCT00996892
A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered Daily in Patients With Locally Advanced or Metastatic Solid Tumors
1
       
GDC-0980
NCT00854152
A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma
1
       
GDC-0980
NCT00854126
A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma
1
       
MP470
NCT00504205
MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma
1
       
SNX-5422
NCT00644072
SNX-5422 in Treating Patients With Solid Tumor or Lymphoma That Has Not Responded to Treatment
1
       
Vorinostat + Bortezomib
NCT00227513
Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors
1
       
AMG 479 + AMG 655
NCT00819169
AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
2
       
Sunitinib + Radiation
NCT00463060
Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer
2
       
AT13387
NCT00878423
Phase 1 Study of HSP90 inhibitor AT13387 in solid tumors
1
       
BAY 73-4506
Phase I study of BAY 73-4506
1
       
BEZ235
NCT00620594
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
1
       

 

81  Records found   Page 1 of 2 | Next | Last